Glancy
Binkow & Goldberg LLP reminds investors of InVivo
Therapeutics Holdings Corp. (“InVivo” or the “Company”) (OTC:NVIV)
that all purchasers of InVivo securities between April 5, 2013 and
August 26, 2013, inclusive (the “Class Period”), have until October 6,
2014, to file a motion to be appointed as lead plaintiff in the
shareholder lawsuit.
InVivo develops biomaterial technologies for the treatment of spinal
cord injuries and hydrogels for therapeutics delivery. The Complaint
alleges that defendants made false and/or misleading statements and
failed to disclose material adverse facts about the Company’s business,
operations and prospects. Specifically, defendants misrepresented and/or
failed to disclose that the Company’s clinical study for its biopolymer
scaffolding to treat acute spinal cord injuries would not be completed
with all data submitted to the FDA by the end of 2014, and the Company
did not anticipate completing this clinical study until late 2015. As a
result, the Company’s statements about its clinical study timeline for
biopolymer scaffolding to treat acute spinal cord injuries were
materially false and misleading and/or lacked a reasonable basis.
If you are a member of the Class described above, you may move the Court
no later than October 6, 2014, to serve as lead plaintiff; however, you
must meet certain legal requirements. To be a member of the Class, you
need not take any action at this time; you may retain counsel of your
choice or take no action and remain an absent member of the Class. If
you wish to learn
more about this action or have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Lesley
Portnoy, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park
East, Suite 2100, Los Angeles, California 90067, Toll-Free at
888-773-9224, by e-mail to shareholders@glancylaw.com,
or visit our website at http://www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Copyright Business Wire 2014